Drug intelligence / Profile preview

DDO-3055

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DDO-3055 is an orally administered small molecule drug developed by Jiangsu Hengrui Medicine for the treatment of anemia, particularly anemia associated with chronic kidney disease. It acts as a prolyl hydroxylase domain-containing protein 2 (PHD2) inhibitor, which stabilizes hypoxia-inducible factors and stimulates erythropoiesis. The drug has reached Phase I clinical trials in China for anemia in adults and elderly patients, including those with chronic kidney disease[1][3][4][6][8].

Other names: UNII-EDZ8BK9GK2UNII-EDZ-8BK9GK2UNII-EDZ 8BK9GK2

Targets

EGLN1 (Prolyl hydroxylase domain-containing protein 2)

Beyond the preview

Go deeper on DDO-3055.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DDO-3055.

Explore the full profile